Matrix metalloproteinase-9 (MMP-9) is up-regulated in ulcerative colitis and implicated in the pathology of the disease. In this study, we have examined the effects of a barbiturate-based MMP inhibitor incorporating a nitric oxide donor/mimetic group (dinitrate-barbiturate) on the intestinal injury induced by dextran sulphate sodium (DSS).
Introduction
The precise interaction of host and environmental factors operative in the aetiology of ulcerative colitis (UC) remains incompletely defined. The prevailing hypothesis at present postulates that gut inflammation is triggered in genetically susceptible individuals in response to gut microbes or other environmental factors through impaired barrier function or a dysregulated immune response (Sartor, 2006) . The matrix metalloproteases (MMPs) are a family of zinc-dependent endopeptidases with a known involvement in intestinal inflammation. Collectively, they are capable of digesting most components of the extracellular matrix and targeting constituents of epithelial junctional complexes, thereby promoting gut barrier dysfunction (Medina and Radomski, 2006) . MMP-9 in particular has been shown to be up-regulated in inflammatory bowel disease (IBD) (Medina et al., 2006a) and positively correlated with disease severity (Medina et al., 2006b; Garg et al., 2009; O'Sullivan et al., 2015) . Therefore, MMP-9 seems to be an attractive drug target to ameliorate intestinal inflammation. However, earlier attempts at MMP inhibition have failed in clinical trials for cancer, showing poor efficacy and dose-limiting side effects attributed to inadequate MMP subtype specificity (Zucker et al., 2000) . Even in inflammatory conditions, the MMPs, including MMP-9, continue to perform physiological functions. Therefore, new approaches for MMP-9 inhibition would focus on correcting the dysregulated enzyme activity specifically associated with the pathophysiology of disease. MMP-9 is mainly regulated at transcriptional level by several pro-inflammatory transcription factors. The promoter region of the MMP-9 gene (Mmp9)contains binding sites for NF-κB, AP-1, PEA3, and SP-1). NO can impair the signalling cascades of several pro-inflammatory pathways including NF-κB, AP-1 and SP-1 signalling. Indeed, S-nitrosothiols inhibited p50 nuclear translocation and NF-κB DNA binding, thus reducing TNF-α-mediated Mmp9 expression (Okamoto et al., 2002) .
Interestingly, transcription factors, including AP-1, that are activated by cGMP are also regulated by NO through protein modification (Marshall et al., 2000) . However, the interplay between NO and MMP-9 is complex and sometimes contradictory, as some studies have shown the effect of NO on MMP-9 activation (O'Sullivan et al., 2013) .
We have previously reported the design of a new type of anti-inflammatory hybrid in which an NO-mimetic group is integrated into an enzyme level inhibitor of MMP-9. The hybrids have a dual mode of action being able to inhibit MMP-9 intrinsically and, following NO release or metabolism, have been shown to inhibit MMP-9 secretion from CACO-2 cells (Wang et al., 2012) . NO releasing hybrids have been reported with several other classes of clinically effective drugs, including non-steroidal anti-inflammatory drugs (Keeble and Moore, 2002; Rigas and Kashfi, 2004; Thatcher et al., 2004; Yeh et al., 2004) nitro-aspirins , NO-glucocorticoids (Fiorucci et al., 2002; Paul-Clark et al., 2002; Turesin et al., 2003) and NO-salbutamol (Lagente et al., 2004; Turner et al., 2010) .
In this study, we tested the pharmacological effects of a previously described dinitrate-barbiturate, MMP-9 inhibitor compound 1a on intestinal injury, in a rat model of distal colitis induced by dextran sulphate sodium (DSS). We have also compared the effects of compound (1a) with those of the non-nitrate equivalent and side chain alone. Compound 1a has been shown to be a low nanomolar inhibitor of MMP-9 in phorbol-12-myristate-13-acetate (PMA)-stimulated HT-1080 cells and in cytokine-stimulated CACO-2 cells (Wang et al., 2012) . The DSS rat model exhibits clinical and morphological features resembling human UC, including diarrhoea and rectal bleeding, diffuse lesions circumscribed to the mucosa and predominance of distal involvement of the large intestine (Okayasu et al., 1990) . Meta-analyses have shown the efficacy of rectally administered drugs such as 5-aminosalicylic acid as induction therapy in patients with mild to moderate UC proctitis or left-sided UC (Marshall Ford et al., 2012) , and our compounds were administered rectally to ensure maximum local concentration in the bowel. We hypothesized that barbiturate-based MMP inhibitor incorporating a NO moiety could further reduce intestinal injury and the expression of inflammation-related genes in DSS-induced colitis.
Methods

Animals
All animal care and experimental procedures in this study were approved by the Animal Ethics Committee of Trinity College Dublin. Animals were maintained in a restrictedaccess room at 23°C with 12 h:12 h light-dark cycles and were housed in rack-mounted cages with a maximum of five rats per cage. Standard food pellets and tap water were provided ad libitum. In vivo experiments and animal studies are reported in compliance with the ARRIVE guidelines (Kilkenny et al., 2010; McGrath & Lilley, 2015) . A total of 50 male Wistar rats weighing 200-220 g (Bioresources Unit, Trinity College Dublin, Ireland) were used. The DSS rat model was chosen as it has been in use for many years to study colonic inflammation (Kiesler et al., 2015) .
Effects of the dinitrate-barbiturate compound in the DSS model of colitis
In this study, we tested compound 1a (5-(4-phenoxyphenyl)-5-(bis-(2-nitrooxy-ethyl)-amino)pyrimidine-2,4,6(1H,3H,5H)-trione), a barbiturate scaffold with two nitrate moieties on its side chain that yielded the greatest increase in NO x À after 24 h of the series of nitrates; 2a (5-(4-phenoxyphenyl)-5-(Bis-(2-hydroxyethyl)-amino)pyrimidine-2,4,6(1H,3H,5H)-trione), an analogous compound to 1a with hydroxyl groups replacing the nitrates and 3a (bis-(2-nitrooxy-ethyl)-amine), the dinitrate side chain alone, without the barbiturate scaffold (Wang et al., 2012) (Supporing Information Figure S1 ). Animals were randomly allocated to the different treatment groups. Distal colitis was induced by oral DSS (molecular wt 40,000; TdB consultancy, Uppsala, Sweden) at 5% (w/v) in tap water ad libitum for 5 days in the colitic groups (Okayasu et al., 1990) , whereas the sham group only received plain water (n = 10, each group). Animals were given twice daily, 500 μL rectal enemas of vehicle (1% Cremophor, 5% ethanol in double-distilled H 2 O) or compounds 1a, 2a or 3a dissolved in the vehicle to give 1.8 μM solutions (calculated from an approximate 2 mg·kg À1 dose in 500 μL for compound 1a). The rats were weighed each morning for the duration of the experiment and examined for diarrhoea and evidence of blood in the stool or rectal bleeding. Normal stools were defined as well formed pellets, loose stools as pasty and semi-formed stools which do not stick to the anus, and diarrhoea was defined as the presence of faecal matter adherent to the fur around the fur or tail. Rectal bleeding was defined as the visible presence of blood around the rectal area of the rat (Cooper et al., 1993; Naito et al., 2004) . The disease activity index (DAI) was calculated by assigning scores to changes in body weight (0: <1%; 1: 1-5%; 2: 5-10%; 3: 10-15%; and 4: >15%), rectal bleeding (0: negative; 2: presence of blood in the stool; and 4: gross rectal bleeding) and stool consistency (0: normal; 2: soft; and 4: diarrhoea). These results were averaged to a give a maximum possible score of 4, as described previously (Islam et al., 2014) . On day 5, the endpoint of the experiment, all animals were individually killed in a CO 2 chamber at a flow rate of 4 L·min À1 . After death, a mid-laparotomy was performed and the colon was removed, opened longitudinally, rinsed with sterile saline and divided into two parts by a longitudinal section. One specimen was processed for histological assessment of mucosal lesions. The second specimen was cut and snap frozen in liquid nitrogen for MMP assays and placed in RNAlater solution (Ambion, Ireland) and frozen for future isolation of mRNA.
Histological assessment of colon samples
Distal colon sections were placed in neutral buffered 10% formalin for 48 h for fixing and then transferred to 70% ethanol for storage. Thereafter, the fixed colon samples were pretreated using a Leica TP 1020 automated tissue processor and embedded in molten paraffin using a Leica EG-1150H. Tissue sections (7 μm) were then cut using a rotary microtome and placed on poly-lysine subbed slides. Routine haematoxylin and eosin (H & E) staining was carried out using a linear stainer (Leica ST4020) and examined by light microscopy. Transverse and longitudinal colon sections were analysed at a minimum of three random locations to obtain an indiscriminate representation of tissue state from which to establish histopathological scores, and these scores were averaged. Histological scoring was based on a modified version of a protocol employed previously (Cooper et al., 1993) where two histological parameters were employed in order to establish the severity of DSS-induced colitis. Tissue inflammation was graded on a scale of 0-3 as follows: 0 -no visible enlargement of lamina propria; 1 -mild enlargement of lamina propria; 2 -moderate expansion of lamina propria with increased infiltration of inflammatory cells; 3 -substantial increase in lamina propria size in addition to heavy infiltration of nuclei into surrounding areas. Crypt damage was graded on a scale of 0-4, where: 0 -intact crypts extending down to muscularis mucosae; 1 -shortening and loss of basal 1/3 of crypt; 2 -loss of basal 2/3 of crypts and focal thinning of epithelium; 3 -total loss of crypts with retention of surface epithelium; 4 -total loss of crypts with surface erosions.
Based on the criteria outlined above, individual scores were assigned to each area of the section analysed by three experienced scientists (ND, NB and SKL) who were unaware of the treatment groups. In cases where the tissue section exhibited varying grades of pathology, the highest score was recorded. Average scores were then obtained for each sample, reflecting the extent of DSS-induced colonic damage or inflammation. The total scores for crypt damage and tissue inflammation were summed to give a score of total inflammation.
Colon sections were digitally scanned (40× magnification) by Slidepath, and these images were visualized using Digital Slidebox software. To determine the average crypt length, areas from longitudinal colon sections were measured using the annotation functions across five areas of each sample and averaged.
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Gelatin zymography
The activity of MMP-2 and MMP-9 was measured as previously described (Medina et al., 2003; Wang et al., 2012) in homogenates of colonic tissue. Briefly, colonic samples were homogenized and mixed with electrophoresis loading buffer (10:1; v/v). Thereafter, samples were analysed by electrophoresis on 8% SDS-PAGE copolymerized with gelatine (2 mg·mL À1 ). After electrophoresis, gels were washed with 2.5% Triton X-100 for 1 h (three times, 20 min each) and incubated for 48 h in enzyme assay buffer (25 mM Tris, ph 7.5, 5 mM CaCl 2 , 0.9% NaCl, 0.05% Na 3 N) for the development of enzyme activity bands. After incubation, the gels were stained with 0.05% Coomassie brilliant blue G-250 in a mixture of methanol-acetic acid-water (2.5:1:6.5) and destained in 4% methanol with 8% acetic acid. The gelatinolytic activities were detected as transparent bands against the background of Coomassie brilliant blue-stained gelatine. The intensities of the separate bands were analysed using ChemiDoc XRS System (Bio-Rad, Hercules, CA, USA). The activity of MMPs was normalized to the protein content of the sample.
Quantitative PCR
Quantitative PCR (qPCR) was used to measure Mmp9 expression in distal colon samples. Briefly, the RNA was isolated using RNAqueous-4PCR® kit from Ambion (Applied Biosystems, Warrington, Cheshire, UK) according to the manufacturer's protocol. The concentration and purity of the RNA yielded was measured using the NanoDrop ND-1000 (Thermo Fisher Scientific, Wilmington, USA). RNA samples were converted to singlestranded cDNA using a High Capacity cDNA Reverse Transcription kit (Applied Biosystems, UK). As target primer/probes, TaqMan assay MMP-9: Rn 00579162_m1 was used, and endogenous 18 s rRNA (Hs 99999901_s1) was used as a control. Heat cycles required for PCR were run on Realplex 2 Mastercycler (Eppendorf, Stevenage, UK) and consisted of step 1, 95°C for 10 min, step 2, 95°C for 15 s and step 3, 60°C for 60 s. Steps 2 and 3 were repeated for 40 cycles, and the measuring point for the reaction was set at the 60°C step. Relative quantitation was calculated for each sample using the formula 2-ΔΔCt where ΔCt = Ct(gene of interest)ÀCt(internal control;18 s) and ΔΔCt = ΔCt(sample of interest)ÀΔCt(median animal of the sham group). Using this method, the calculated value for the median animal in the sham group will be 1, and other values will be fold change in transcripts relative to this animal. This method is standard for comparing gene expression between samples where absolute transcript numbers are not required.
TaqMan low density array cards
Rat inflammation microfluidic cards (Applied Biosystems, UK) were used to measure the expression of 91 different inflammatory genes. mRNA was isolated from distal colon samples as described above. The samples were normalized for RNA concentration, and reverse transcription was carried
Figure 1
Progression of disease activity over the course of the experiment as measured by the DAI. (A) DAI scores for each day for all groups (10 animals in each group). Histograms of the DAI scores for the rats on day 4 (B) and day 5 (C) when statistically significant differences were observed following treatment with compound 1a, 2a or 3a. *P < 0.05, significantly different from sham; #P < 0.05, significantly different from DSS control group.
out using high-capacity cDNA reverse transcription kit (Applied Biosystems, UK) according to the manufacturer's instructions. qPCR was performed on each sample in duplicate using a Viia 7 (Applied Biosystems, UK) default settings for array cards. Quantification analysis was carried out using the 2 À(ΔΔCT) method, with 18 s as the internal control, and expression calculated relative to a chosen median animal in the sham control group. Following relative quantification, a cut-off point of twofold up-or down-regulated was chosen. The Venn diagram online software, Venny (Oliveros, 2007) , was used to identify genes that were commonly up-or down-regulated in all animals of the sham and 1a treated groups relative to the DSS group. A correlation matrix was generated using the dChip software (Li and Wong, 2001 ) to assess the correlation of gene expression profiles of animals within and between experimental groups. This clusters samples together based on the gene expression profile. The degree of correlation is given a colour to allow visualization with positive correlations relating to the brightness of the red colour and negative correlations given by the brightness of the green colour. Following clustering, the samples are presented as in a square where the colour of the box at the intersection of two samples indicates the degree of correlation.
Data and statistical analysis
Data in the graphs are presented as the means ± SEM. Analysis of results was carried out using Graph Pad Prism® 5 for Windows (Graph Pad software, USA). Groups which contained five or more independent repeats were subjected to statistical analysis to comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2015) . Results were analysed using a one-way ANOVA; Dunnett's post hoc test was run only if F achieved P < 0.05. Linear regression analysis was used for correlations with R 2 and P values quoted. P values of <0.05 were taken to indicate statistical significance.
Materials
Compounds 1a, 2a, 3a were prepared in-house as previously described (Wang et al., (2012) . Compound identity was confirmed by comparison with the original description Wang et al., 2012) , using high resolution NMR and MS techniques, and compound purity was assessed by HPLC.
Results
Dinitrate-barbiturate (compound 1a) reduces the disease activity index and histological damage in DSS-induced colitis
The mean DAI score for sham group animals never changed from zero as shown in Figure 1 . Exposure to 5% DSS in drinking water for 5 days induced diarrhoea and rectal bleeding in all rats in the DSS (vehicle) group. Colitic animals that received compound 1a showed significantly lower DAI score when compared with the DSS group by day 4, and a further reduction on day 5. Colitic animals that received compound 2a had a reduction in the DAI score only on day 5. The nitrate side-chain by itself, compound 3a, by itself had no statistically significant effect.
Next, we studied the relationship between the DAI score and the histological damage. For this purpose, representative samples from all groups were stained with H&E and analysed for histological signs of inflammation ( Figure 2A) . First, the histological examination revealed no changes in colons of the sham control animals. As expected, oral administration of 5% DSS resulted in severe injury of the colonic epithelium and loss of normal crypt architecture, with some areas of erosion. A mixed infiltrate of neutrophils and mononuclear cells was observed in the lamina propria. Figures 2B and C show the crypt length and total inflammation scores in all groups. The DSS treatment significantly increased the total inflammation score which was mitigated by compound 1a. Compounds 2a and 3a did not significantly reduce the inflammation score. In addition, the hybrid compound reduced the effect of the DSS on crypt length. DAI and total inflammation score were positively correlated (P < 0.05, R 2 = 0.63, Figure 2D ).
Compound 1a reduces MMP-9 activity and expression in the distal colon
As we had previously demonstrated that barbiturate-nitrate hybrids were able to inhibit MMP-9 in vitro (Wang et al., 2012), we next studied the effect of compound 1a on MMP-9 in DSS-induced colitis. DSS treatment increased MMP-9 activity and gene expression, compared with the sham control group ( Figure 3A and B). However, MMP-2 remained unchanged. Interestingly, compound 1a inhibited MMP-9 up-regulation in colitic animals ( Figure 3A and B).
Compounds 2a and 3a showed a trend towards reduced Mmp9 mRNA or activity but the results did not reach statistical significance ( Figure 3A and B). These results correlate well with those seen in Figure 1 and 2 where the hybrid compound provided a greater reduction in inflammation than its component parts. In addition, the levels of Mmp9 mRNA showed close correspondence with both total inflammation score (P < 0.05, R 2 = 0.5497) and DAI score (P < 0.05, R 2 = 0.682) as shown in Figure 3C and D respectively.
The effect of compound 1a on expression of inflammatory regulators in the distal colon
To further characterize the effects of the inhibition of MMP, by compound 1a, on intestinal inflammation, we studied the expression of mRNA from 91 inflammation-related genes using TaqMan microfluidic card low-density PCR array technology (full list of genes in Supporting Information Table S1 ). Relative quantitation was carried out and a correlation matrix was generated to assess the correlation of gene expression profile with animal experiment group (Figure 4) . From the correlation matrix, all but one of the DSS group animals clustered together and had strong correlation. Similarly, the sham group and the 1a-treated group clustered together. Following relative quantitation, genes from the sham and the 1a-treated groups that were up or down-regulated more than two-fold relative to the DSS control group were assessed for common elements. Four genes were found to be commonly up-regulated by two fold or more in three or more samples of the sham and 1a-treated groups, relative to the DSS group and 30 genes were found to be commonly down-regulated by two-fold or more in three or more of the sham and 1a-treated groups, relative to the DSS group. We next focused on the genes where the highest differences between the DSS group and the 1a-treated group were found. As the levels of Mmp9 mRNA showed significant correspondence with both histological and DAI scores, we next studied significant correlations between inflammatory genes and Mmp9 mRNA.
Genes encoding IL family receptors
Treatment with the hybrid compound 1a altered the expression of genes for several IL family receptors, particularly the IL 2 receptor. The expression of IL-2 receptor subunit β (IL2rb) and IL-2 receptor subunit γ (IL2rg) was similar in both the sham group and DSS control group. Interestingly, mRNA from both IL2rb and IL2rg genes increased in the 1a-treated group compared with the DSS group ( Figure 5A ). On the other hand, the expression of two other proteins, IL 1 receptor-like 1 (IL1rl1) and IL 1 receptor-like 2 (IL1r2), was increased in the DSS control group compared with the sham group, an effect that was abolished by compound 1a ( Figure 5A ). In addition, the expression of these genes showed positive correlations with Mmp9 expression rates (IL1rl1 P < 0.05, R 2 = 0.55; IL1r2 P = 0.05, R 2 = 0.3405) where a reduction in Mmp9 expression following treatment with compound 1a also corresponded to a reduction in the expression of these receptors ( Figure 5B and C).
Genes encoding mediators of lipid metabolism and eicosanoid synthesis
Treatment of animals with compound 1a affected the expression of genes for several enzymes and factors involved in the synthesis of eicosanoids. DSS induced the up-regulation of the genes for 12S-LOX (Alox12), annexin A3 (Anxa3) and phospholipase A 2 (Pla2g2a), compared with those in the sham group, an effect that was abolished by treatment with compound 1a ( Figure 6A ). Of these, the expression of Anxa3 (P < 0.05, R 2 = 0.48) and Pla2g2a (P < 0.05, R 2 = 0.33) were positively correlated with expression of Mmp9 ( Figure 6B and C).
Genes encoding other inflammatory mediators
The expression of Bdkrb1, the gene for the bradykinin B 1 receptor was increased by DSS compared with the sham group, however, Bdkrb1 expression returned to basal levels in the 1a-treated group ( Figure 7A ). This pattern of expression significantly correlated positively with Mmp9 (P = 0.05, R 2 = 0.4) ( Figure 7B ). The expression of genes for caspase-1 and the kallikrein related peptidase 7 (Klk7) was reduced by DSS compared with the sham group, an effect which was reversed by the treatment with compound 1a ( Figure 7A ). The expression of Klk7 negatively correlated with Mmp9; thus a lower expression of Mmp9 corresponded to a high expression of Klk7 (P = 0.05, R 2 = 0.35) ( Figure 7C ).
Figure 4
Heatmap of sample correlation of RNA expression levels. Correlation matrix of samples from sham (n = 4), DSS (n = 7) and compound 1a (n = 4) groups used in gene expression profiling, generated using dChip software. The level of correlation of the gene expression profile of two samples is indicated by the colour of the intersection. As shown in the colour key, green colour represents lower correlation (Pearson's r) and red colour indicates higher correlation.
Discussion
The aetiology of IBD remains to be elucidated, but a close correlation between the level of MMP-9 and the severity of the disease has been found (O'Sullivan et al., 2015) . In this study, we investigated the ability of an MMP-9 inhibitor with NO-mimetic properties to inhibit Mmp9 expression and inflammation in the DSS model of colitis. This is a commonly used model of UC and deficiency in MMP-9 attenuated the severity of DSS-induced colitis in mice (Santana et al., 2006) . In addition, constitutive expression of MMP-9 in intestinal epithelium exacerbated DSS-induced colitis and was associated with increased levels of proinflammatory cytokines (Liu et al., 2013) . To gain further insight into the effect of the inhibition of MMP-9 by compound 1a, on intestinal inflammation, we also studied its effect on the expression of inflammation-related genes.
The interplay between NO and MMP-9 is complex. For instance, endogenous and pharmacologically derived NO could inhibit MMP-9 transcription or activity, by interacting with different signalling pathways. On the other hand, high levels of NO can catalyse oxidation of the inhibitory cysteine on its prodomain causing activation of pro-MMP-9. Here, we have tested a barbiturate-based MMP inhibitor incorporating a NO moiety, in vivo, to study its pharmacological effects in an inflammatory condition, DSS-induced colitis, where inducible MMP-9 plays an important role. Incorporation of a nitrate group was intended to confer on the compound an ability to modulate the enzyme levels of MMP-9 in order to complement the direct inhibition of the enzyme by the barbiturate zinc binding group. As other MMPs are less susceptible to induction by pathophysiological stimuli, these compounds indeed possess potential to exhibit a functional selectivity that would not be apparent in a simple active site inhibitor. We have previously shown that the hybrid compound 1a is a true hybrid, being an nM inhibitor of MMP-9 and an organic nitrate that can mimic the effects of NO. Organic nitrates, especially primary nitrates such as compound 1a, are rapidly metabolized in vivo, producing nitrite. Nitrates mimic the effects of NO, most likely through further intracellular reduction of nitrite to NO. The mechanism of the NO-like activity in this old drug class remains unresolved. NO is difficult to detect as a byproduct of nitrate metabolism in vivo or in vitro, but the effects of organic nitrates such as stimulation of sGC are similar to NO donors, about which there is no dispute, and so it is widely believed that nitrates act as NO donors. Compound 1a was previously shown to release nitrite/nitrate in cultures of colorectal cells over 24 h, in a concentration-dependent manner. (Wang et al., 2012) . We have previously shown that compound 1a inhibited MMP-9 activity at enzyme level and also its secretion from PMA-stimulated HT-1080 cells and TNFα/IL1β-stimulated CACO-2 cells (Wang et al., 2012) . The inhibitory effect on MMP-9 secretion of a panel of nitrate Nitrate inhibition of MMP-9 in DSS-induced colitis BJP hybrids was attributed to the NO mimicry because analogues without the nitrate group, though still able to inhibit MMP-9 enzyme activity, did not inhibit secretion. In the current study, the hybrid compound 1a significantly inhibited disease activity, an effect which was observed as early as on day 4 of DSS administration. The MMP-9 inhibitor analogue that has no NO mimetic properties (compound 2a) reduced the DAI score on day 5. The NO mimetic side chain by itself (compound 3a) had no significant effect on DAI or related inflammatory markers. Compound 1a also reduced histological measures of inflammation in the distal colon and was able to inhibit Mmp9 expression. Additionally, in agreement with our previous study (Medina et al., 2003) , there was a significant relationship between the levels of Mmp9 mRNA and the DAI and total inflammation score. Taken together, these results strengthen the potential for MMP inhibition as a therapy for IBD which mirrors the findings of many other groups (see Marshall et al., 2015; O'Sullivan et al., 2015) . Our findings also suggest the potential for the use of NO-MMP inhibitors in the treatment of colitis where the NO-mimetic properties of the molecule confer a greater ability to inhibit MMP-9 and inflammation. Our studies reveal, therefore, an additive effect or an alternative mechanism of action for compound 1a potentially due to the combination of inhibition of MMP-9 at enzyme level and NO-mimetic effects. However, further investigation is needed to reveal the precise molecular mechanisms by which the nitrate moiety in the hybrid compound contributes to the reduction in MMP-9 activity.
Although the main objective of the study was to determine whether the use of NO-MMPI had a greater inhibitory effect in MMP-9 and DSS-induced colitis, we next studied the impact of 1a on a panel of inflammation-related genes. This gave us the opportunity to gain a wider view of the effects of the compound on expression of proteins relating to inflammation in the colon.
Initial analysis of the TaqMan inflammatory array results shows that the expression profiles of all but one of the DSS group cluster together; whereas the sham and 1a-treated group clustered together which is evidence in and of itself of the ability of the hybrid compound to attenuate the induced colitis.
Interestingly, the IL2rb and IL2rg genes which encode for IL 2 receptor sub-units β and γ were up-regulated in the group treated with compound 1a. The IL-2 receptor is critical for the function of anti-inflammatory regulatory T cells (Suzuki et al., 1995; Malek and Bayer, 2004; Malek, 2008) . Therefore, up-regulation of IL2rb and IL2rg following treatment with compound 1a could represent a novel and very interesting anti-inflammatory mechanism, Compound 1a also reduced Figure 6 Relative levels of expression of mRNA for proteins involved in lipid metabolism and eicosanoid generation in the distal colon in sham group, DSS group and compound 1a-treated animals. (A) Relative expression of Alox12 mRNA, Anxa3 mRNA and Pla2g2a mRNA. Positive relationship between Anxa3 and MMP-9 mRNA (B) and between Pla2g2a and MMP-9 mRNA (C).
the expression of IL1rl1 and IL1r2. The protein IL1rl1, also known as ST-2 when stimulated, can activate MAPKs but inhibits NF-κB signalling, resulting in a dominant Th2 and not Th1 type response through inhibition of the IL1r1 response (Brint et al., 2004) . The ligand for ST-2 is IL-33, and several lines of evidence point to this pathway being a promising drug target in IBD (Salas, 2013) . Both IL-33 and ST-2 are up-regulated in IBD patients (Beltran et al., 2010; Pastorelli et al., 2010) as was seen in our animal model. A recent study on the blocking of this pathway in animal models using gene knock outs or an anti-ST-2 antibody found that blocking of IL-33/ST-2 signalling attenuated colitis in animal models, including the DSS model (Sedhom et al., 2013) . In addition, polymorphisms of the IL1R2 gene are associated with UC (Anderson et al., 2011) , and the expression profile of the receptor is associated with mucosal healing in UC with potential as a biomarker (Roman et al., 2013) .
Treatment with compound 1a also reduced the expression of mRNA for several proteins involved in the generation of eicosanoids, including those encoded by Pla2g2a, Anxa3 and Alox12. Phospholipase A2 is known to be up-regulated in IBD and correlates with the severity of the disease (Minami et al., 1992; Haapamaki et al., 1999a; Haapamaki et al., 1999b) , and its inhibition can protect from experimental colitis (Krimsky et al., 2003; Tomita et al., 2003; Woodruff et al., 2005) . Annexin A3 is a known inhibitor of phospholipase A2 (Davidson et al., 1987) and is up-regulated in an inflammatory setting without itself mediating the inflammation. The Alox12 gene codes for 12S-LOX, which metabolizes arachidonic acid to generate bioactive lipids.
The treatment with compound 1a also resulted in a down-regulation of mRNA for the bradykinin B 1 receptor, from Bdkrb1, and up-regulation of that for caspase-1 (casp1) and the protease (Klk7). Expression of the B 1 receptor is induced during inflammation and mediates the inflammatory effects of bradykinin including release of gelatinases (Ehrenfeld et al., 2014) . Our results suggest a close correlation between the levels of mRNA for the B 1 receptor and MMP-9. Therefore, inhibition of the de novo synthesis of this receptor could potentially be a novel mechanism of MMP-9 inhibition. Some studies with caspase-1 À/À mice have shown a detrimental rather than a protective role for caspase-1 in DSS-induced colitis (Thornberry et al., 1992; Zaki et al., 2010) which would be in agreement with our findings. The kallikrein-like enzyme, Klk7, is a serine protease whose main function is understood to be in skin homeostasis. Although
Figure 7
Relative levels of expression of mRNA for some other proteins involved in inflammation in the distal colon in sham group, DSS group and compound 1a-treated animals. Nitrate inhibition of MMP-9 in DSS-induced colitis BJP this protease is associated with poor prognosis in colon cancer (Talieri et al., 2009; Devetzi et al., 2013) , few other studies have been carried out on its role in the gut. Particularly, no studies have been carried out, so far, in experimental colitis and/or human IBD. Our results showed a negative relationship between Klk7 and Mmp9 mRNA and further studies are needed in order to identify its role in intestinal inflammation.
In conclusion, our results demonstrate the efficacy of the dinitrate-barbiturate compound 1a, an MMP-9 inhibitor, in reducing colonic inflammation in the DSS model. This improvement was greater than that observed with the unsubsituted MMP-9 inhibitor or the dinitrate component alone. In the past, NO hybrids have shown promise in cancer and airway inflammation, but this study represents a novel approach to MMP-9 inhibition. Hence, barbiturate-nitrate hybrids could provide a valuable therapy in patients suffering from IBD. We have also analysed the effect of the compound on the expression of other mediators of inflammation in the colon. Although further experiments are needed to corroborate these results, the initial TaqMan array analysis showed that compound 1a attenuated DSS-induced colitis as the sham and 1a-treated groups clustered together. The exact effect of compound 1a on these inflammatory genes remains to be studied. Whether these genes are co-expressed with Mmp9 and compound 1a blocks their transcriptional up-regulation, whether the inhibition of MMP-9 results in lower overall inflammation and thus a reduction in expression of these genes or whether the reduction in the expression of one or some of these genes represents a novel mechanism of MMP-9 inhibition, are all questions that remain to be answered.
